CRISPR Therapeutics CRSP Grant — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's grant — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's grant — revenue?
- CRISPR Therapeutics (CRSP) reported grant — revenue of $458K in Q1 2026.
- How has CRISPR Therapeutics's grant — revenue changed year-over-year?
- CRISPR Therapeutics's grant — revenue decreased by 47.1% year-over-year, from $865K to $458K.
- What is the long-term trend for CRISPR Therapeutics's grant — revenue?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's grant — revenue has grown at a 16.9% compound annual growth rate (CAGR), from $1.88M to $3.51M.
- What does grant — revenue mean?
- This metric represents the revenue recognized from government or institutional grants and research contracts, excluding any associated tax assessments. It reflects the financial support received for specific research and development initiatives, serving as a key indicator of non-dilutive funding for early-stage therapeutic programs. This revenue stream highlights the company's ability to secure external validation and financial backing for its proprietary gene-editing technology platforms.